We would like to thank the wider OPTIMISE-CKD study team for their support with the data, definitions, and real-world context used in this analysis. The authors would also like to acknowledge the Health, Clinic, and Education Information Evaluation Institute for the database development for the study.

Under the direction of the authors, medical writing support for this summary of research was provided by Caitlin Edgell, PhD, of Oxford PharmaGenesis, Oxford, UK, and was funded by AstraZeneca.